TY - JOUR
T1 - Inhibitory effects of herbal extracts on breast cancer resistance protein (BCRP) and structure-inhibitory potency relationship of isoflavonoids
AU - Tamaki, Hirofumi
AU - Satoh, Hiroki
AU - Hori, Satoko
AU - Ohtani, Hisakazu
AU - Sawada, Yasufumi
N1 - Funding Information:
Received; September 10, 2009, Accepted; December 24, 2009 *To whom correspondence should be addressed: Yasufumi SAWADA, Laboratory of Drug Informatics, Graduate School of Pharmaceutical Science, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan. Tel.+81-3-5841-2270, Fax.+81-3-5841-1097, E-mail address: sawada@mol.f.u-tokyo.ac.jp This study was supported in part by the Foundation for Total Health Promotion and the Mochida Memorial Foundation for Medical and Pharmaceutical Research.
PY - 2010
Y1 - 2010
N2 - The inhibition of intestinal breast cancer resistance protein (BCRP), which restricts the absorption of xenobiotics, may increase the systemic availability of its substrates. The aim of this study was to evaluate the inhibitory effects of herbal extracts and their constituents on BCRP-mediated transport. The inhibitory effects of 9 herbal extracts and 23 isoflavonoids, including soybean-derived isoflavones, on BCRP-mediated methotrexate (MTX) transport were evaluated using BCRP-expressing membrane vesicles. The structure-in-hibitory potency relationship was investigated by multiple factor analysis. Extracts of soybean, Gymnema sylvestre, black cohosh and passion flower and rutin strongly inhibited BCRP-mediated transport of MTX at 1 mg/ml, while inhibition by chlorella, milk thistle and Siberian ginseng extracts was weak. Among the 23 isoflavonoids examined, all of which inhibited BCRP-mediated transport, coumestrol showed the most potent inhibition (IC50=63 nM). The inhibitory potencies of 6 isoflavonoid glucosides were 10-to 100-fold lower than those of the corresponding aglycones. The addition of a 5-hydroxyl or 6-methoxyl moiety tended to potentiate the inhibition. The inhibitory potency of daidzein was decreased 100-fold by 7-glucuronidation, but was virtually unaffected by 4′-sulfation. Thus, some herbal and dietary supplements and isoflavonoids may increase the systemic availability of BCRP substrates when concomitantly given orally.
AB - The inhibition of intestinal breast cancer resistance protein (BCRP), which restricts the absorption of xenobiotics, may increase the systemic availability of its substrates. The aim of this study was to evaluate the inhibitory effects of herbal extracts and their constituents on BCRP-mediated transport. The inhibitory effects of 9 herbal extracts and 23 isoflavonoids, including soybean-derived isoflavones, on BCRP-mediated methotrexate (MTX) transport were evaluated using BCRP-expressing membrane vesicles. The structure-in-hibitory potency relationship was investigated by multiple factor analysis. Extracts of soybean, Gymnema sylvestre, black cohosh and passion flower and rutin strongly inhibited BCRP-mediated transport of MTX at 1 mg/ml, while inhibition by chlorella, milk thistle and Siberian ginseng extracts was weak. Among the 23 isoflavonoids examined, all of which inhibited BCRP-mediated transport, coumestrol showed the most potent inhibition (IC50=63 nM). The inhibitory potencies of 6 isoflavonoid glucosides were 10-to 100-fold lower than those of the corresponding aglycones. The addition of a 5-hydroxyl or 6-methoxyl moiety tended to potentiate the inhibition. The inhibitory potency of daidzein was decreased 100-fold by 7-glucuronidation, but was virtually unaffected by 4′-sulfation. Thus, some herbal and dietary supplements and isoflavonoids may increase the systemic availability of BCRP substrates when concomitantly given orally.
KW - ATP-binding cassette transporter G2 (ABCG2)
KW - Breast cancer resistance protein (BCRP)
KW - Dietary supplement
KW - Drug interactions
KW - Isoflavonoids
KW - Structure-activity relationship
UR - http://www.scopus.com/inward/record.url?scp=77952652033&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77952652033&partnerID=8YFLogxK
U2 - 10.2133/dmpk.25.170
DO - 10.2133/dmpk.25.170
M3 - Article
C2 - 20460823
AN - SCOPUS:77952652033
SN - 1347-4367
VL - 25
SP - 170
EP - 179
JO - Drug Metabolism And Pharmacokinetics
JF - Drug Metabolism And Pharmacokinetics
IS - 2
ER -